Statistical considerations in clinical trial design with event‐free survival as the primary efficacy endpoint
Authors:
- 16 February 2021
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 20 (4) , 721-736
Abstract
In late‐phase confirmatory clinical trials in the oncology field, time‐to‐event (TTE) endpoints are commonly used as primary endpoints for establishing the efficacy of investigational therapies. Among these TTE endpoints, overall survival (OS) is always considered as the gold standard. However, OS data can take years to mature, and its use for measurement of efficacy can be confounded by the use of post‐treatment rescue therapies or supportive care. Therefore, to accelerate the development process and better characterize the treatment effect of new investigational therapies, other TTE endpoints such as progression‐free survival and event‐free survival (EFS) are applied as primary efficacy endpoints in some confirmatory trials, either as a surrogate for OS or as a direct measure of clinical benefits. For evaluating novel treatments for acute myeloid leukemia, EFS has been gradually recognized as a direct measure of clinical benefits. However, the application of an EFS endpoint is still controversial mainly due to the debate surrounding definition of treatment failure (TF) events. In this article, we investigate the EFS endpoint with the most conservative definition for the timing of TF, which is Day 1 since randomization. Specifically, the corresponding non‐proportional hazard pattern of the EFS endpoint is investigated with both analytical and numerical approaches.Keywords
This publication has 20 references indexed in Scilit:
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRIHaematologica, 2016
- New drug approvals in acute myeloid leukemia: what’s the best end point?Leukemia, 2015
- Tumor Volumes and Prognosis in Laryngeal CancerCancers, 2015
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood, 2015
- Management of older or unfit patients with acute myeloid leukemiaLeukemia, 2014
- Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 2010
- Weighted Kaplan-Meier Statistics: A Class of Distance Tests for Censored Survival DataBiometrics, 1989
- The asymptotic properties of nonparametric tests for comparing survival distributionsBiometrika, 1981
- The Monte Carlo MethodJournal of the American Statistical Association, 1949